KR102059918B1 - 돌연변이형 렌티바이러스 env 단백질 및 이의 약물로서의 용도 - Google Patents

돌연변이형 렌티바이러스 env 단백질 및 이의 약물로서의 용도 Download PDF

Info

Publication number
KR102059918B1
KR102059918B1 KR1020147018840A KR20147018840A KR102059918B1 KR 102059918 B1 KR102059918 B1 KR 102059918B1 KR 1020147018840 A KR1020147018840 A KR 1020147018840A KR 20147018840 A KR20147018840 A KR 20147018840A KR 102059918 B1 KR102059918 B1 KR 102059918B1
Authority
KR
South Korea
Prior art keywords
seq
mutant
protein
env protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147018840A
Other languages
English (en)
Korean (ko)
Other versions
KR20140116091A (ko
Inventor
띠에리 에이드만
Original Assignee
비록시스 에스.아.에스.
상뜨르 나쇼날 드 라 러쉐르쉬 샹띠피끄
유니베르시떼 파리스-쉬드
엥스띠뛰 귀스따브 루씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비록시스 에스.아.에스., 상뜨르 나쇼날 드 라 러쉐르쉬 샹띠피끄, 유니베르시떼 파리스-쉬드, 엥스띠뛰 귀스따브 루씨 filed Critical 비록시스 에스.아.에스.
Publication of KR20140116091A publication Critical patent/KR20140116091A/ko
Application granted granted Critical
Publication of KR102059918B1 publication Critical patent/KR102059918B1/ko
Assigned to 유니베르시떼 파리-싸끌레 reassignment 유니베르시떼 파리-싸끌레 권리지분의 전부이전등록 Assignors: 유니베르시떼 파리스-쉬드
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020147018840A 2011-12-07 2012-12-07 돌연변이형 렌티바이러스 env 단백질 및 이의 약물로서의 용도 Expired - Fee Related KR102059918B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11306625 2011-12-07
EP11306625.2 2011-12-07
PCT/EP2012/074835 WO2013083799A1 (en) 2011-12-07 2012-12-07 Mutated lentiviral env proteins and their use as drugs

Publications (2)

Publication Number Publication Date
KR20140116091A KR20140116091A (ko) 2014-10-01
KR102059918B1 true KR102059918B1 (ko) 2020-02-11

Family

ID=47435901

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147018840A Expired - Fee Related KR102059918B1 (ko) 2011-12-07 2012-12-07 돌연변이형 렌티바이러스 env 단백질 및 이의 약물로서의 용도

Country Status (16)

Country Link
US (1) US9682137B2 (cg-RX-API-DMAC10.html)
EP (1) EP2788372B1 (cg-RX-API-DMAC10.html)
JP (2) JP6415324B2 (cg-RX-API-DMAC10.html)
KR (1) KR102059918B1 (cg-RX-API-DMAC10.html)
CN (1) CN104169295B (cg-RX-API-DMAC10.html)
AU (1) AU2012350258B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014013704B1 (cg-RX-API-DMAC10.html)
CA (1) CA2856180C (cg-RX-API-DMAC10.html)
DK (1) DK2788372T3 (cg-RX-API-DMAC10.html)
ES (1) ES2748864T3 (cg-RX-API-DMAC10.html)
IL (1) IL232926B (cg-RX-API-DMAC10.html)
IN (1) IN2014CN04927A (cg-RX-API-DMAC10.html)
MX (1) MX350689B (cg-RX-API-DMAC10.html)
RU (1) RU2654673C2 (cg-RX-API-DMAC10.html)
WO (1) WO2013083799A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201403617B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351247B2 (en) * 2017-09-01 2022-06-07 Inprother Aps Vaccine for use in the prophylaxis and/or treatment of a disease
CN117500931A (zh) * 2021-01-13 2024-02-02 维洛克塞斯 麻疹-hiv或麻疹-htlv疫苗
US20240093233A1 (en) 2021-01-13 2024-03-21 Viroxis Measles-hiv or measles-htlv vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022740A2 (en) * 2008-08-28 2010-03-04 Aarhus Universitet Hiv-1 envelope polypeptides for hiv vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
WO2005012502A2 (en) 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
AU2005229411B2 (en) * 2004-03-30 2010-11-18 Centre National De La Recherche Scientifique Polypeptide sequence involved in the modulation of the immunosuppressive effect of viral proteins
EP2420248A1 (en) 2004-08-17 2012-02-22 Institut Gustave Roussy Mutated HIV NEF for modulating immunity
RU2426788C1 (ru) * 2010-03-01 2011-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ЦНИИЭ Роспотребнадзора) Генетические конструкции для антивич-терапии

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022740A2 (en) * 2008-08-28 2010-03-04 Aarhus Universitet Hiv-1 envelope polypeptides for hiv vaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Clinical Immunology and Immunopathology. Vol. 71, No. 3, pp. 315-324 (1994)*

Also Published As

Publication number Publication date
DK2788372T3 (da) 2019-10-14
RU2654673C2 (ru) 2018-05-21
JP2018150370A (ja) 2018-09-27
AU2012350258B2 (en) 2017-03-02
ES2748864T3 (es) 2020-03-18
RU2014127521A (ru) 2016-02-10
IN2014CN04927A (cg-RX-API-DMAC10.html) 2015-09-18
EP2788372A1 (en) 2014-10-15
EP2788372B1 (en) 2019-07-10
AU2012350258A8 (en) 2014-07-17
US9682137B2 (en) 2017-06-20
IL232926A0 (en) 2014-07-31
CN104169295B (zh) 2020-07-28
BR112014013704B1 (pt) 2023-01-31
CA2856180C (en) 2022-09-06
MX2014006744A (es) 2014-12-08
JP2015505836A (ja) 2015-02-26
MX350689B (es) 2017-09-13
BR112014013704A2 (pt) 2021-02-17
AU2012350258A1 (en) 2014-06-05
CN104169295A (zh) 2014-11-26
WO2013083799A1 (en) 2013-06-13
IL232926B (en) 2019-01-31
CA2856180A1 (en) 2013-06-13
ZA201403617B (en) 2015-07-29
US20140294880A1 (en) 2014-10-02
JP6415324B2 (ja) 2018-10-31
KR20140116091A (ko) 2014-10-01

Similar Documents

Publication Publication Date Title
US10946090B2 (en) Consensus/ancestral immunogens
AU2018283811B2 (en) Poxvirus vectors encoding HIV antigens, and methods of use thereof
CA2505583C (en) Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
US8048431B2 (en) Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
JP2018150370A (ja) レンチウイルスの変異ｅｎｖタンパク質及び薬物としてのその使用
CA3204201A1 (en) Measles-hiv or measles-htlv vaccine
EP3004143B1 (en) Mutated non-primate lentiviral env proteins and their use as drugs
US9636396B2 (en) Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
US20200206342A1 (en) Engineered variants of hiv-1 env for presentation of quartenary epitopes
Warner et al. Human immunodeficiency virus immunotherapy using a retroviral vector
AU2017200429A1 (en) Consensus/Ancestral Immunogens

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20220829

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20241221

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20241221

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20241221